Exploring clozapine use in severe psychiatric symptoms associated with autism spectrum disorder: A sco** review

ALST da Rosa, OS Bezerra, LA Rohde… - Journal of …, 2024 - journals.sagepub.com
Background: Patients with autism spectrum disorder (ASD) may experience severe
psychiatric symptoms, often unresponsive to conventional pharmacological therapies …

When, why and how to re-challenge Clozapine in Schizophrenia following myocarditis

M Qubad, G Dupont, M Hahn, SS Martin, V Puntmann… - CNS drugs, 2024 - Springer
Clozapine-induced myocarditis (CIM) is among the most important adverse events limiting
the use of clozapine as the most effective treatment for schizophrenia. CIM necessitates the …

[HTML][HTML] Enhancing predictive power: Integrating a linear support vector classifier with logistic regression for patient outcome prognosis in virtual reality therapy for …

A Hudon, M Beaudoin, K Phraxayavong… - Journal of personalized …, 2023 - mdpi.com
(1) Background: Approximately 30% of schizophrenia patients are known to be treatment-
resistant. For these cases, more personalized approaches must be developed. Virtual reality …

Prevalence of treatment-resistant schizophrenia among people with early psychosis and its clinical and demographic correlates

M Detanac, C Williams, M Dragovic… - Australian & New …, 2024 - journals.sagepub.com
Objective: The prevalence of treatment-resistant schizophrenia (TRS) among people with
first-episode schizophrenia (FES) has been sub-optimally researched in Australia and …

Real-World Treatment of Schizophrenia in Adults With a 22q11. 2 Microdeletion: Traitement dans le monde réel de la schizophrénie chez des adultes atteints du …

L Van, T Heung, NGD Reyes, E Boot… - The Canadian …, 2024 - journals.sagepub.com
Résumé Objectif Une personne sur quatre atteinte du syndrome de microdélétion 22q11. 2
développera une schizophrénie. Les tests génétiques cliniques développés depuis 30 ans …

The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force

H Verdoux, RA Bittner, A Hasan, M Qubad… - European …, 2025 - cambridge.org
The European Clozapine Task Force is a group of psychiatrists and pharmacologists
practicing in 18 countries under European Medicines Agency (EMA) regulation, who are …

Investigando o potencial da clozapina no tratamento de sintomas psiquiátricos graves associados ao transtorno do espectro autista

ALST Rosa - 2023 - lume.ufrgs.br
Introdução: Indivíduos com transtorno do espectro autista (TEA) exibem uma elevada
prevalência de comorbidades psiquiátricas e comportamentos desafiadores. A abordagem …